×
Tectonic Therapeutic Net Cash Flow 2017-2025 | TECX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Tectonic Therapeutic net cash flow from 2017 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
View More
Tectonic Therapeutic Net Cash Flow 2017-2025 | TECX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Tectonic Therapeutic net cash flow from 2017 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$213.3B
Amgen (AMGN)
$158.5B
Gilead Sciences (GILD)
$134.6B
Vertex Pharmaceuticals (VRTX)
$118.1B
Bristol Myers Squibb (BMY)
$96.4B
CSL (CSLLY)
$81.2B
GSK (GSK)
$74.3B
Regeneron Pharmaceuticals (REGN)
$58.6B
Alnylam Pharmaceuticals (ALNY)
$41.8B
Argenex SE (ARGX)
$34.6B
BioNTech SE (BNTX)
$26.4B
Royalty Pharma (RPRX)
$20B
Insmed (INSM)
$19.5B
Biogen (BIIB)
$18.3B
Illumina (ILMN)
$15.2B
Genmab (GNMSF)
$14.3B
Genmab (GMAB)
$14B
Incyte (INCY)
$13.1B
Exelixis (EXEL)
$12.1B
Moderna (MRNA)
$12.1B
BioMarin Pharmaceutical (BMRN)
$11B
QIAGEN (QGEN)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Ascendis Pharma (ASND)
$10.4B
Exact Sciences (EXAS)
$9.5B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Blueprint Medicines (BPMC)
$8.3B
Bio-Techne Corp (TECH)
$8.2B
Roivant Sciences (ROIV)
$7.8B
Legend Biotech (LEGN)
$7.6B